US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
To-be Listed (Grey Market Trading Session: 16:15-18:30)
Name
/
Code
Industry Listing Price Lot Size Entry Fee Phillip Grey Market Futu (HK) Grey Market
SAINT BELLA
02508.HK
Grey Market Today
Health Care Services 6.580 500 N/A
-
-
Detail Quote
Zhou Liu Fu
06168.HK
Grey Market Today
Watch & Jewellery 24.000 100 N/A
-
-
Detail Quote
Eternal Beauty
06883.HK
Grey Market Today
Beauty & Toiletries Products and Services Pending 1,000 3,414
-
-
Detail Quote
Last update: 2025-06-24 12:30:05
Name
/
Code
Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date
Listing Date
Medtide
03880.HK
Biotechnology - Pharmaceuticals 28.4-30.6 100 3,091 2025/06/25 2025/06/27 2025/06/30
IFBH
06603.HK
Beverages (Non-alcoholic) 25.3-27.8 200 5,616 2025/06/25 2025/06/27 2025/06/30
Unisound
09678.HK
Advanced hardware and software 165-205 20 4,141 2025/06/25 2025/06/27 2025/06/30
Cloudbreak-B
02592.HK
Biotechnology - Pharmaceuticals 10.1 500 N/A 2025/06/27 2025/07/02 2025/07/03
Summary
We are a clinical-stage ophthalmology biotechnology company dedicated to the development of various treatments. Ophthalmology is a branch of medical science dealing with the structure, function and diseases of the eyes. Our history traces back to 2015 upon the establishment of our Group. We have two Core Products, CBT-001 and CBT-009, both of which are being proprietarily developed. Our Core Product CBT-001 is indicated for the treatment of pterygium (a benign proliferative ocular surface disease), and we have commenced phase 3 multi-regional clinical trial (“MRCT”) in the United States and China in June 2022 and September 2023 respectively for it. Our Core Product CBT-009 is indicated for the treatment of juvenile myopia (myopia in children and adolescents aged 5 to 19), and we have completed the phase 1/2 clinical trial in January 2023 and submitted the investigational new drug (“IND”) application to the United States Food and Drug Administration (“FDA”) in July 2024 for it. Our other drug candidates are in relatively earlier development stage, including two other clinical-stage drug candidates, which are CBT-006 and CBT-004, and four pre-clinical stage drug candidates, which are CBT-007, CBT-199, CBT-145, and CBT-011.

However, the market potential for these Core Products might be limited and the market opportunities may be smaller than expected, because of unfavourable factors including but not limited to, inaccurate estimations on target patient populations, penetration in and/ or difficulty in accessing the medical community and patients. See “Risk Factors – Risks Relating to the Development, Clinical Trials and Regulatory Approval of Our Drug Candidates – The market opportunities for our drug candidates may be smaller than we anticipate for reasons including the presence of existing multiple prevention methods and treatment options, which could render some drug candidates ultimately unprofitable even if commercialised” for details.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET ANY OF OUR DRUG CANDIDATES SUCCESSFULLY.

All of our four clinical-stage drug candidates have adopted the 505(b)(2) regulatory pathway. The 505(b)(2) regulatory pathway is applicable to modified new drugs that were developed based on previously approved reference drugs with modifications in dosage forms, routes of administration, formulation and/or new indications.



Source: Cloudbreak-B (02592) Prospectus (IPO Date : 2025/06/24)
Listing Market MAIN
Industry Biotechnology - Pharmaceuticals
Background Others
Major Business Area N/A
Corporate Information
Substantial Shareholders Ni Jinsong (29.23%)
Bright Future Pharmaceutical Laboratories Ltd. (11.38%)
Van Son Dinh (8.02%)
Skketch Shine Limited (5.92%)
Yicun Holdings Limited (5.59%)
Directors NI Jinsong (Chairman and Chief Executive Officer and Executive Director)
Van Son DINH (Chief Operating Officer and Executive Director)
YANG Rong (Chief Scientific Officer and Executive Director)
CAO Xu (Non-Executive Director)
LI Jun Zhi (Non-Executive Director)
XIA Zhidong (Non-Executive Director)
LAI Hin Wing Henry Stephen (Independent Non-Executive Director)
LIU Chung Mun (Independent Non-Executive Director)
NIE Sijiang (Independent Non-Executive Director)
Company Secretary AU Thomas Tsz Ngai
FUNG Nga Fong
Principal Bankers China Construction Bank (Asia) Corporation Limited
Solicitors Haiwen & Partners
Hogan Lovells
Jun He Law Offices
Harney Westwood & Riegels
Auditors PricewaterhouseCoopers
Registered Office Unit 2308, 23/F., Lippo Centre Tower 1, 89 Queensway, Hong Kong
Share Registrars Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No (852) 2980-1333
Internet Address http://www.cloudbreakpharma.com
Email Address
Tel No
Fax No
 
SITEMAP
Email: support@aastocks.com
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.